Extensive-stage Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
This is a randomized, multi-center, open-label study of approximately 24 months duration (including follow up survival) to evaluate the safety and efficacy of obatoclax mesylate in combination with carboplatin and etoposide versus carboplatin and etoposide alone in chemotherapy-naive patients with extensive-stage small cell lung cancer.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 2018 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - The patient has histologic or cytologic confirmation (upon local review) of small cell lung cancer (SCLC). - The patient has extensive-stage small cell lung cancer (ES-SCLC), as defined by National Comprehensive Cancer Network (NCCN) guidelines. - The patient has measurable disease as assessed by Response Evaluation Criteria Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). - The patient has not received any prior chemotherapy, biological agent, or investigational drug for SCLC. - The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - The patient is 18 years of age or older at the time informed consent is obtained. - The patient must be accessible for study treatment and follow-up. Patients enrolled in this study must be treated at participating study centers for all 3 days of study drug administration in either treatment group. - The patient has normal organ function. - Women of childbearing potential must have a negative serum pregnancy test 72 hours prior to study enrollment. Women of childbearing potential and men with partners of childbearing potential must use a highly effective method of contraception throughout the entire study and up to 8 weeks after the last dose of any study drug (including obatoclax maintenance). Effective contraception or birth control is defined as those with a low failure rate (less than 1% per year) when used consistently and correctly. - Women must not be breastfeeding. - Written informed consent is obtained. - Patients with asymptomatic brain metastases may be enrolled and if clinically indicated, may be treated with steroids to be tapered as tolerated by the patient. Patients with symptomatic brain metastases will be eligible for the study after they have received therapeutic whole brain irradiation (WBI), which must be completed at least 7 days before the day of first treatment with study drugs. Since these patients will also be treated with steroids it is recommended that steroids be tapered as clinically indicated and tolerated by the patient. The use of chronic, low-dose steroids is not contraindicated for these patients (or any other patients). Stereotactic radiation will be allowed for 1 to 3 brain metastatic lesions that meet appropriate criteria for that procedure; however, this must be discussed with the study monitor prior to consideration for enrollment into this study. - The patient must be willing and able to comply with study restrictions and to remain at the study center for the required duration during the study period and willing to return to the study center for the follow-up evaluation as specified in this protocol. Exclusion Criteria: - The patient has had any prior systemic therapy for ES-SCLC other than radiation therapy or surgery. - The patient has a history of prior malignancy with the exception of cervical intraepithelial neoplasia, basal cell or squamous cell carcinoma of the skin, or other localized malignancy that has undergone potentially curative therapy and is deemed by his or her treating physician to be at low risk for recurrence for 5 years. - The patient has a history of hypersensitivity or allergic reactions attributed to components of the obatoclax mesylate formulation (ie, polysorbate 20 and polyethylene glycol [PEG] 300) or to carboplatin or etoposide. - The patient currently has leptomeningeal disease or paraneoplastic syndromes. - The patient has uncontrolled intercurrent illness including, but not limited to, symptomatic neurologic illness; active, uncontrolled systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment; symptomatic congestive heart failure; unstable angina pectoris; clinically significant cardiac arrhythmia; significant pulmonary disease or hypoxia; or psychiatric illness that would limit compliance with study requirements. - The patient is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study but will be monitored for safety.) - The patient has a positive test result for hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C virus (HCV Ab) or a known positive history of antibodies to human immunodeficiency virus (HIV) and is receiving combination antiretroviral therapy. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Cephalon |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival (OS): Time to Death | After 570 death events have been observed (Interim Analysis after 171 death events)or 24 months from last patient enrolled | 24 months from last patient enrolled | No |
Secondary | Progression-Free Survival (PFS) | Randomization to Date of First Documented Disease Progression or Death for up to 24 months from last patient enrolled | 24 months from last patient enrolled | No |
Secondary | Duration of Response | First Response to Disease Progression or Death up to 24 months from last patient enrolled | 24 months from last patient enrolled | No |
Secondary | Objective Response Rate (Complete Response or Partial Response) | 37 months | No | |
Secondary | Quality of Life | This is assessed with the European Organization for Research and Treatment of Cancer(EORTC)QLQ-C30 and EORTC QLQ-LC13 questionnaires | 37 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05509699 -
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05975944 -
Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04562337 -
A Phase II Clinical Study of SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in Extensive Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00616109 -
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
|
Phase 2 | |
Active, not recruiting |
NCT04373369 -
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04254471 -
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04774380 -
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
|
Phase 3 | |
Active, not recruiting |
NCT01555710 -
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
|
Phase 3 | |
Completed |
NCT00682981 -
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04397003 -
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04702880 -
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04487756 -
Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03135977 -
Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
|
Phase 2 | |
Completed |
NCT03913455 -
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04663438 -
Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC
|
||
Not yet recruiting |
NCT03971214 -
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT04101357 -
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
|
Phase 1/Phase 2 | |
Completed |
NCT04636762 -
A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
Not yet recruiting |
NCT04404543 -
A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT02323737 -
Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer
|
Phase 2 |